Biotechnology Market Size and Outlook 2030

Report Description

Forecast Period	2026-2030
Market Size (2024)	USD 1.45 Trillion
CAGR (2025-2030)	12.85%
Fastest Growing Segment	Biopharmaceuticals
Largest Market	North America
Market Size (2030)	USD 2.99 Trillion

Market Overview

The Global Biotechnology Market, valued at USD 1.45 Trillion in 2024, is projected to experience a CAGR of 12.85% to reach USD 2.99 Trillion by 2030. Biotechnology encompasses the application of biological systems and processes to develop products and technologies that advance human health, agriculture, and industrial processes. Key drivers supporting the market's expansion include the increasing global prevalence of chronic and infectious diseases, necessitating advanced therapeutic and diagnostic solutions, alongside continuous advancements in genomics, molecular biology, and genetic engineering. The growing demand for personalized medicine also provides substantial impetus for market development.

A significant challenge impeding market growth is the substantial capital investment required for extensive research and development activities, further complicated by protracted and intricate regulatory approval pathways. According to the European Federation of Pharmaceutical Industries and Associations, in 2023, an estimated €50,000 million was invested in pharmaceutical research and development in Europe, underscoring the considerable financial commitment inherent in this innovative sector.

Key Market Drivers

The biotechnology market is significantly propelled by breakthroughs in genetic engineering and gene editing technologies. These advancements, exemplified by tools such as CRISPR, enable precise modifications to genetic material, offering unprecedented potential for treating diseases at their root cause. This has led to a rapid expansion in therapeutic development, moving beyond conventional small molecules and biologics. This momentum is clearly reflected in regulatory milestones, as according to RegMedNet, May 2025, FDA-Approved Cell and Gene Therapies, the US Food and Drug Administration approved nine cell and gene therapy products in 2024, signaling a robust pipeline translating into tangible patient solutions. Concurrently, the growing demand for personalized medicine and advanced biotherapeutics represents another critical driver. Patients and healthcare systems increasingly seek treatments tailored to individual genetic profiles and disease characteristics, moving away from a one-size-fits-all approach. This shift necessitates sophisticated diagnostic tools and targeted therapies, fostering innovation in areas like companion diagnostics and stratified medicine. A major pharmaceutical company, Roche, announced plans in April 2025 to invest $50 billion into its US pharmaceutical and diagnostics operations over five years, supporting its pioneering role in personalized healthcare.

These two drivers together are reshaping the landscape of drug discovery and development, fostering an environment of accelerated innovation and increasing therapeutic efficacy across numerous disease areas. The synergistic evolution of these factors not only broadens the scope of biotechnology applications in human health but also necessitates substantial research and development efforts across the industry. This collective pursuit of innovative solutions underscores the dynamic growth within the sector. Reflecting this broader inventive activity, according to the World Intellectual Property Organization, in 2024, patent applications in biotechnology grew by 6.4% in 2023.

Download Free Sample Report

Key Market Challenges

The substantial capital investment necessitated by extensive research and development activities presents a considerable impediment to the growth of the global biotechnology market. Developing innovative biological systems and processes demands significant, long-term financial commitments, often over many years before a product can reach commercialization. This inherent financial burden acts as a barrier, particularly for smaller biotechnology firms, limiting their capacity to pursue novel therapeutic and diagnostic solutions. For larger entities, the high costs can lead to a more conservative investment strategy, focusing resources on fewer, higher-probability projects, which can slow the overall pace of innovation and restrict the diversity of product pipelines across the industry.

The scale of this financial undertaking is considerable. According to PhRMA, in 2023, its member companies invested approximately $96 billion in research and development. Such immense funding requirements divert capital that could otherwise be allocated to expanding manufacturing capabilities, market penetration, or supporting early-stage research into diverse therapeutic areas. Consequently, the rigorous demands of R&D investment directly constrain the potential for widespread market expansion and the rapid introduction of new biotechnological advancements.

Key Market Trends

Two significant trends shaping the global biotechnology market are the accelerating integration of AI-powered drug discovery and development, and the advancements in synthetic biology for bio-production. These trends demonstrate distinct influences on market dynamics.

The adoption of artificial intelligence in drug discovery and development is revolutionizing the pharmaceutical pipeline by enhancing the speed and efficiency of identifying drug candidates, optimizing lead compounds, and predicting clinical outcomes. This technology reduces the time and cost traditionally associated with bringing new therapies to market. For instance, according to the Massachusetts Biotechnology Council, Massachusetts-headquartered biopharma companies collectively received $7.89 billion in venture capital funding in 2024, reflecting substantial investment in innovation that includes AI-driven methodologies. Further illustrating this trend, Bexorg, Inc. announced the completion of a $23 million Series A financing in October 2025, specifically aimed at advancing its integrated AI and whole-human brain platform for central nervous system drug discovery and development.

Concurrently, advancements in synthetic biology are driving significant growth in bio-production, enabling the engineering of biological systems for manufacturing a diverse range of products, from sustainable chemicals to novel materials. This focus extends beyond traditional human health applications into industrial and agricultural sectors, emphasizing efficiency and environmental sustainability. EuropaBio’s 2024 annual report highlighted that biotechnology and biomanufacturing achieved unprecedented political attention, recognized as integral to Europe's industrial, competitive, and sustainable future, underscored by the European Commission's Communication “Building the future with nature: Boosting Biotechnology and Biomanufacturing in the EU”. A pertinent example of this trend is Liberation Labs, a precision fermentation company, which secured a $50 million funding round in March 2025 to finalize its 600,000-liter precision fermentation facility dedicated to producing bio-based ingredients for food, chemicals, and industrial applications.

Segmental Insights

The biopharmaceutical segment is identified as the fastest-growing sector within the global biotechnology market, driven by several critical factors. This rapid expansion is primarily attributed to the increasing global prevalence of chronic diseases and an aging population, which together fuel a significant demand for innovative and effective treatments. Furthermore, biopharmaceuticals offer advanced, targeted therapies with enhanced specificity and fewer side effects compared to traditional pharmaceutical products, addressing previously unmet medical needs. Concurrently, significant investments in research and development, alongside supportive regulatory frameworks from bodies such as the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), facilitate expedited approvals for novel biological drugs, further accelerating segmental growth.

Regional Insights

North America leads the global biotechnology market due to its robust innovation ecosystem and substantial investments in research and development activities. The region benefits from a significant presence of leading biopharmaceutical companies and advanced technological infrastructure, fostering continuous advancements in areas like genomics and personalized medicine. Furthermore, a supportive regulatory environment, characterized by established bodies such as the U. S. Food and Drug Administration, facilitates product development and market access. This combination of strong funding, key industry players, and a clear regulatory landscape underpins North America's dominance in biotechnology.

Recent Developments

In October 2025, Nabla Bio and Takeda announced an extended multi-year research collaboration aimed at advancing the AI-driven design of protein therapeutics within the Global Biotechnology Market. This partnership leverages Nabla Bio's proprietary Joint Atomic Model (JAM) platform across Takeda's early-stage development programs, encompassing the de novo design of antibodies and other custom therapeutics for various targets. Under the terms of the agreement, Nabla Bio is set to receive double-digit millions in upfront and research cost payments, with eligibility for success-based payments that could exceed $1 billion in total.

In October 2025, QUANTRO Therapeutics and Boehringer Ingelheim extended their strategic collaboration for an additional two years to develop first-in-class drug candidates targeting cancer-associated transcription factors. This partnership within the Global Biotechnology Market focuses on addressing high unmet needs in cancer patients. The extension followed the successful completion of a high-throughput screening campaign and the identification of promising compounds for further development. QUANTRO is eligible to receive success-based R&D, regulatory, and commercial milestone payments up to an estimated total value of around €500 million.

In June 2024, Tropic Biosciences achieved a significant milestone in agricultural biotechnology with the clearance of its reduced browning bananas in the Philippines as non-genetically modified organisms (GMOs). These bananas were developed utilizing the CRISPR-Cas9 gene editing system. This innovation, relevant to the Global Biotechnology Market, addresses food waste and aims to reduce carbon dioxide emissions, equivalent to removing two million cars annually. The Certificates of Non-Coverage were issued by the Department of Agriculture – Bureau of Plant Industry.

In January 2024, the biotechnology sector marked a historic achievement with the regulatory approval of Casgevy, the world's first CRISPR-based therapy. Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, this breakthrough treatment received authorization for addressing sickle cell disease. This approval represented a pivotal moment for genetic medicine, bringing clinical gene editing into mainstream therapeutic applications within the Global Biotechnology Market and signaling significant advancements in the treatment of genetic disorders.

Key Market Players

Novo Nordisk A/S
Regeneron Pharmaceuticals Inc.
Amgen, Inc.
CSL Limited
Gilead Sciences, Inc.
Celgene Corporation
Biogen Inc.
Vertex Pharmaceuticals, Inc.
Seagen Inc.
Genmab A/S

By Application	By End User	By Region
Biopharmaceuticals Bio-IT Bio- Industrial Bio-Agriculture	Biotechnology & Pharmaceutical Companies Research Institutes & Laboratories Academic Institutions Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biotechnology Market, By Application:

o Biopharmaceuticals

o Bio-IT

o Bio- Industrial

o Bio-Agriculture

Biotechnology Market, By End User:

o Biotechnology & Pharmaceutical Companies

o Research Institutes & Laboratories

o Academic Institutions

o Others

Biotechnology Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biotechnology Market.

Available Customizations:

Global Biotechnology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Biotechnology Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biotechnology Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Application (Biopharmaceuticals, Bio-IT, Bio- Industrial, Bio-Agriculture)

5.2.2. By End User (Biotechnology & Pharmaceutical Companies, Research Institutes & Laboratories, Academic Institutions, Others)

5.2.3. By Region

5.2.4. By Company (2024)

5.3. Market Map

6. North America Biotechnology Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Application

6.2.2. By End User

6.2.3. By Country

6.3. North America: Country Analysis

6.3.1. United States Biotechnology Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Application

6.3.1.2.2. By End User

6.3.2. Canada Biotechnology Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Application

6.3.2.2.2. By End User

6.3.3. Mexico Biotechnology Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Application

6.3.3.2.2. By End User

7. Europe Biotechnology Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Application

7.2.2. By End User

7.2.3. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Biotechnology Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Application

7.3.1.2.2. By End User

7.3.2. France Biotechnology Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Application

7.3.2.2.2. By End User

7.3.3. United Kingdom Biotechnology Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Application

7.3.3.2.2. By End User

7.3.4. Italy Biotechnology Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Application

7.3.4.2.2. By End User

7.3.5. Spain Biotechnology Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Application

7.3.5.2.2. By End User

8. Asia Pacific Biotechnology Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Application

8.2.2. By End User

8.2.3. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Biotechnology Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Application

8.3.1.2.2. By End User

8.3.2. India Biotechnology Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Application

8.3.2.2.2. By End User

8.3.3. Japan Biotechnology Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Application

8.3.3.2.2. By End User

8.3.4. South Korea Biotechnology Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Application

8.3.4.2.2. By End User

8.3.5. Australia Biotechnology Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Application

8.3.5.2.2. By End User

9. Middle East & Africa Biotechnology Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Application

9.2.2. By End User

9.2.3. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Biotechnology Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Application

9.3.1.2.2. By End User

9.3.2. UAE Biotechnology Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Application

9.3.2.2.2. By End User

9.3.3. South Africa Biotechnology Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Application

9.3.3.2.2. By End User

10. South America Biotechnology Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Application

10.2.2. By End User

10.2.3. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Biotechnology Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Application

10.3.1.2.2. By End User

10.3.2. Colombia Biotechnology Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Application

10.3.2.2.2. By End User

10.3.3. Argentina Biotechnology Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Application

10.3.3.2.2. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Biotechnology Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Novo Nordisk A/S

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Regeneron Pharmaceuticals Inc.

15.3. Amgen, Inc.

15.4. CSL Limited

15.5. Gilead Sciences, Inc.

15.6. Celgene Corporation

15.7. Biogen Inc.

15.8. Vertex Pharmaceuticals, Inc.

15.9. Seagen Inc.

15.10. Genmab A/S

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Biotechnology Market in 2024?

Which is the dominating region in the Global Biotechnology Market?

Which is the fastest growing segment in the Global Biotechnology Market?

What is the expected growth rate of the Global Biotechnology Market?